NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This trial compares the safety and effectiveness of catheter ablation for PAF with
antiarrhythmic drug therapy. The investigational catheter being studied is the NAVISTAR®
THERMOCOOL® irrigated-tip catheter. At the time of this study, the NAVISTAR® THERMOCOOL®
catheter was FDA-approved for commercial distribution in the U.S. for treating patients with
Type I atrial flutter and drug refractory monomorphic ventricular tachycardia post myocardial
infarction. The catheter was approved for use in Europe for endocardial ablation for treating
cardiac arrhythmias.